CYTOKINETICS, INCORPORATED Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CYTOKINETICS, INCORPORATED (CYTK) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $170.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $170.00K, a 95.14% decline year-over-year.
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was -$172.00K.
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $2.93M, a 1377.78% increase year-over-year.
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $6.25M, a 1200.42% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $481.00K.
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CYTOKINETICS, INCORPORATED right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $10.90M, a 86.44% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $170.00K 10-Q · filed 2026-08-06 | -$2.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.92M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $170.00K 10-Q · filed 2026-05-05 | -$2.00K derived: sum of 2 quarters · filed 2026-05-05 | $2.92M derived: sum of 3 quarters · filed 2026-05-05 | $2.92M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.75M derived: sum of 2 quarters · filed 2026-02-26 | $2.75M derived: sum of 3 quarters · filed 2026-08-06 | $6.25M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $2.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.93M derived: sum of 2 quarters · filed 2026-08-06 | $6.43M 10-Q · filed 2025-11-05 | $6.40M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.50M 10-Q · filed 2026-08-06 | $3.47M derived: sum of 3 quarters · filed 2026-08-06 | $3.67M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.50M 10-Q · filed 2026-05-05 | $3.47M derived: sum of 2 quarters · filed 2026-05-05 | $3.67M derived: sum of 3 quarters · filed 2026-05-05 | $3.80M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $170.00K derived: sum of 2 quarters · filed 2026-02-26 | $303.00K derived: sum of 3 quarters · filed 2026-02-26 | $481.00K 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $331.00K derived: sum of 2 quarters · filed 2025-11-05 | $509.00K 10-Q · filed 2025-11-05 | $509.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $311.00K 10-Q · filed 2025-08-07 | $311.00K derived: sum of 3 quarters · filed 2026-02-26 | $311.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $178.00K 10-Q · filed 2025-05-06 | $178.00K derived: sum of 2 quarters · filed 2026-02-26 | $178.00K derived: sum of 3 quarters · filed 2026-02-26 | $178.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $8.59M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $8.59M derived: sum of 3 quarters · filed 2025-02-27 | $9.85M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $8.59M derived: sum of 2 quarters · filed 2025-02-27 | $9.85M derived: sum of 3 quarters · filed 2025-02-27 | $10.20M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $9.85M derived: sum of 2 quarters · filed 2025-02-27 | $10.20M derived: sum of 3 quarters · filed 2025-02-27 | $10.90M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.61M derived: sum of 2 quarters · filed 2023-11-03 | $2.31M 10-Q · filed 2023-11-03 | -$501.00K derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $352.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.05M 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2022-08-05 | -$1.76M derived: sum of 3 quarters · filed 2024-02-28 | -$1.76M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $703.00K 10-Q · filed 2023-05-05 | $0.00 10-Q · filed 2022-05-06 | -$2.11M derived: sum of 2 quarters · filed 2024-02-28 | -$2.11M derived: sum of 3 quarters · filed 2024-02-28 | $3.21M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$2.81M derived: sum of 2 quarters · filed 2024-02-28 | $2.51M derived: sum of 3 quarters · filed 2024-02-28 | $80.39M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $5.32M derived: sum of 2 quarters · filed 2022-11-04 | $83.21M 10-Q · filed 2022-11-04 | $83.21M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $83.21M 10-Q · filed 2022-08-05 | $83.21M derived: sum of 3 quarters · filed 2023-03-01 | $83.21M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $77.89M 10-Q · filed 2022-05-06 | $77.89M derived: sum of 2 quarters · filed 2023-03-01 | $77.89M derived: sum of 3 quarters · filed 2023-03-01 | $77.89M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $1.11M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $1.11M 10-Q · filed 2021-11-05 | $1.11M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $1.11M 10-Q · filed 2021-08-06 | $1.11M derived: sum of 3 quarters · filed 2022-02-25 | $1.11M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | $1.11M 10-Q · filed 2021-05-07 | $1.11M derived: sum of 2 quarters · filed 2022-02-25 | $1.11M derived: sum of 3 quarters · filed 2022-02-25 | $1.11M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $1.00K derived: sum of 3 quarters · filed 2022-02-25 | $10.69M 10-K · filed 2022-02-25 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.00K derived: sum of 2 quarters · filed 2020-11-06 | $10.69M 10-Q · filed 2020-11-06 | $10.69M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $10.69M 10-Q · filed 2020-08-07 | $10.69M derived: sum of 3 quarters · filed 2021-02-26 | $10.69M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | $10.69M 10-Q · filed 2020-05-08 | $10.69M derived: sum of 2 quarters · filed 2021-02-26 | $10.69M derived: sum of 3 quarters · filed 2021-02-26 | $10.69M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | $0.00 derived: sum of 3 quarters · filed 2021-02-26 | $0.00 10-K · filed 2021-02-26 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $0.00 derived: sum of 2 quarters · filed 2019-11-01 | $0.00 10-Q · filed 2019-11-01 | |||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |